Eskata
NDC Package 71180-002-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Eskata is none. Marketed by Aclaris Therapeutics, Inc., this product is identified by NDC 71180-002 and is authorized under FDA application NDA209305.

Identification & Billing

NDC Package Code
71180-002-01
Package Description
1 APPLICATOR in 1 CARTON / 520 mg in 1 APPLICATOR
Product Code
71180-002
11-Digit Billing Format
71180000201
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Eskata
Dosage Form
-
Usage Information
None.

Regulatory & Marketing

Labeler Name
Aclaris Therapeutics, Inc.
FDA Application #
NDA209305
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-14-2017
Listing Expiration
12-31-2020
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (71180-002). Click a package code to view its specific billing and regulatory data.

71180-002-03
3 APPLICATOR in 1 CARTON / 520 mg in 1 APPLICATOR
71180-002-12
12 APPLICATOR in 1 CARTON / 520 mg in 1 APPLICATOR

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71180-002-01 identifies a specific commercial package of 1 applicator in 1 carton / 520 mg in 1 applicator of Eskata, labeled by Aclaris Therapeutics, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Aclaris Therapeutics, Inc. on December 14, 2017. The current certification is valid through December 31, 2020.

How is this Aclaris Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71180000201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71180-002-01
11-Digit CMS (5-4-2)
71180-0002-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.